2、公司坚持自主研发的发展战略，始终专注于火盆、气炉等户外休闲家具的研发、生产和销售。经过 多年发展逐步成为拥有完整的研发设计、生产、销售和服务体系的公司；公司家居产品系列丰富，品种 齐全，包括火盆、火盆桌、气炉、气炉桌等各个系列，已经成为国内主要的火盆、气炉类产品的提供商 之一。 来源：新浪证券-红岸工作室 12月3日，雅艺科技跌0.83%，成交额2291.99万元，换手率1.65%，总市值22.80亿元。 异动分析 跨境电商+露营经济+创投+人民币贬值受益 1、2024年年报：2023年公司通过亚马逊平台建立线上销售渠道并推广自有品牌，2024年进一步深化跨 境电商布局。2024年公司营业收入达2.96亿元，同比大幅增长87.22%，显示线上渠道对业绩的强劲拉 动。与此同时，公司积极拓展 TikTok 、wayfair等新兴社交电商平台，利用其精准营销优势触达年轻消 费群体，并借助浙江省跨境电商综合试验区的政策支持，优化海外仓布局与物流效率 。公司以自有品 牌为核心，依托亚马逊扩大市场渗透，提升品牌认知度。 3、公司2023年7月26日公告：浙江雅艺金属科技股份有限公司拟与御道创业投资管理（永康）有限公 ...

Core Viewpoint - Titan Technology's stock has experienced fluctuations, with a year-to-date increase of 23.83% but a recent decline over the past 20 and 60 days, indicating potential volatility in its market performance [1]. Financial Performance - For the period from January to September 2025, Titan Technology reported a revenue of 1.848 billion yuan, representing a year-on-year decrease of 13.06%. However, the net profit attributable to shareholders increased by 15.04% to 11.1678 million yuan [2]. - Cumulative cash dividends since the company's A-share listing amount to 86.6205 million yuan, with 40.1089 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, Titan Technology had 9,293 shareholders, an increase of 20.41% from the previous period. The average number of circulating shares per shareholder decreased by 16.95% to 17,694 shares [2]. Business Overview - Titan Technology, established on October 18, 2007, and listed on October 30, 2020, is based in Shanghai and specializes in providing integrated technical solutions for scientific services, including research reagents, biological consumables, analytical consumables, laboratory instruments, and specialized chemicals. The main revenue sources are research reagents (42.70%), research instruments and consumables (28.42%), and specialized chemicals (26.48%) [1].

今年以来好上好已经15次登上龙虎榜，最近一次登上龙虎榜为11月13日，当日龙虎榜净买入-1.59亿 元；买入总计1.85亿元 ，占总成交额比7.72%；卖出总计3.43亿元 ，占总成交额比14.35%。 资料显示，深圳市好上好信息科技股份有限公司位于广东省深圳市南山区粤海街道高新区社区高新南一 道002号飞亚达科技大厦1501A，成立日期2014年12月23日，上市日期2022年10月31日，公司主营业务 涉及主要向消费电子、物联网、照明等应用领域的电子产品制造商销售电子元器件,并提供相关产品设 计方案和技术支持等服务。主营业务收入构成为：分销业务99.08%，物联网产品设计及制造0.91%，其 他0.01%，芯片定制0.01%。 好上好所属申万行业为：电子-其他电子Ⅱ-其他电子Ⅲ。所属概念板块包括：小盘、存储概念、送转填 权、机器人概念、物联网等。 12月3日，好上好盘中下跌2.09%，截至13:33，报30.46元/股，成交1.44亿元，换手率2.85%，总市值 90.42亿元。 资金流向方面，主力资金净流出889.95万元，特大单买入0.00元，占比0.00%，卖出179.39万元，占比 1.24%；大 ...

资金流向方面，主力资金净流入140.84万元，特大单买入0.00元，占比0.00%，卖出108.75万元，占比 4.02%；大单买入439.97万元，占比16.25%，卖出190.38万元，占比7.03%。 12月3日，聚石化学（维权）盘中下跌2.18%，截至13:29，报21.56元/股，成交2707.93万元，换手率 1.02%，总市值26.16亿元。 资料显示，广东聚石化学股份有限公司位于广东省清远市高新技术产业开发区雄兴工业城B6，成立日 期2007年6月8日，上市日期2021年1月25日，公司主营业务涉及磷化工、改性塑料粒子及制品的研发、 生产和销售。主营业务收入构成为：塑料制品39.30%，改性塑料粒子25.76%，成品油及添加剂 18.71%，磷化学品7.52%，阻燃剂5.31%，贸易原材料2.06%，其他0.77%，其他(补充)0.56%。 聚石化学所属申万行业为：基础化工-塑料-改性塑料。所属概念板块包括：可降解、小盘、钙钛矿电 池、石墨烯、新材料等。 截至9月30日，聚石化学股东户数4754.00，较上期减少5.11%；人均流通股25522股，较上期增加 5.38%。2025年1月-9月， ...

Core Viewpoint - The stock of Yueshen Health has shown significant growth this year, with a 49.13% increase, and recent trading activity indicates strong investor interest [1][2]. Group 1: Stock Performance - As of December 3, Yueshen Health's stock price increased by 2.38% to 5.16 CNY per share, with a trading volume of 1.81 billion CNY and a turnover rate of 3.91%, resulting in a total market capitalization of 47.46 billion CNY [1]. - Year-to-date, Yueshen Health's stock has risen by 49.13%, with a 6.83% increase over the last five trading days, 14.16% over the last 20 days, and 15.70% over the last 60 days [1]. - The company has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on March 19, where it recorded a net buy of -11.8465 million CNY [1]. Group 2: Company Overview - Yueshen Health, established on June 8, 1993, and listed on August 23, 2007, is based in Shanghai and focuses on high-end building ceramics and health-related materials [2]. - The company's main revenue sources include: 35.96% from marble tiles, 31.86% from antique tiles, 11.19% from health services, and smaller percentages from other products [2]. - As of November 30, the number of shareholders stood at 54,800, with an average of 16,763 circulating shares per person [2]. Group 3: Financial Performance - For the period from January to September 2025, Yueshen Health reported a revenue of 771 million CNY, a year-on-year decrease of 13.23%, while the net profit attributable to shareholders was 3.0843 million CNY, reflecting a year-on-year increase of 109.33% [2]. - The company has distributed a total of 89.3 million CNY in dividends since its A-share listing, with no dividends paid in the last three years [3]. - As of September 30, 2025, the top ten circulating shareholders included the Guotai Zhongzheng All-Index Building Materials ETF, which holds 1.9629 million shares as a new shareholder [3].

Core Viewpoint - Hansen Pharmaceutical's stock has shown a positive trend with a year-to-date increase of 17.64%, indicating strong market performance and investor interest [2]. Group 1: Stock Performance - As of December 3, Hansen Pharmaceutical's stock price increased by 2.02%, reaching 7.07 CNY per share, with a trading volume of 46.93 million CNY and a turnover rate of 1.35% [1]. - The stock has experienced a 2.61% increase over the last five trading days, a 7.45% increase over the last 20 days, and a 4.74% increase over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Hansen Pharmaceutical reported a revenue of 741 million CNY, reflecting a year-on-year growth of 6.75%. However, the net profit attributable to shareholders decreased by 36.88% to 82.53 million CNY [2]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 151 million CNY distributed over the past three years [3]. Group 3: Business Overview - Hansen Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, is located in Yiyang, Hunan Province. Its main business includes the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The revenue composition of Hansen Pharmaceutical includes: 54.81% from Si Mo Tang oral liquid, 23.38% from Tian Ma Xing Nao capsules, and smaller contributions from various other products [2]. Group 4: Shareholder Information - As of November 28, 2025, the number of shareholders in Hansen Pharmaceutical increased to 24,100, with an average of 20,618 circulating shares per person, a slight decrease of 0.84% from the previous period [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund is the eighth largest, holding 2.11 million shares as a new shareholder [3].

Core Viewpoint - The stock of Xian Global Printing Co., Ltd. has experienced fluctuations, with a recent decline of 2.03% and a year-to-date increase of 21.24% [1][2]. Financial Performance - For the period from January to September 2025, the company reported a revenue of 619 million yuan, a year-on-year decrease of 44.12%, and a net profit attributable to shareholders of -20.06 million yuan, a decline of 173.05% [2]. - Cumulative cash dividends since the company's A-share listing amount to 72.57 million yuan, with 17.92 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders is 23,800, a decrease of 1.37% from the previous period, while the average circulating shares per person increased by 1.39% to 13,435 shares [2]. - Among the top ten circulating shareholders, Jin Yuan Shun An Yuan Qi Flexible Allocation Mixed Fund holds 1.5481 million shares, an increase of 141,000 shares compared to the previous period [3]. Market Activity - The stock's trading volume on December 3 was 102 million yuan, with a turnover rate of 3.43% and a total market capitalization of 2.941 billion yuan [1]. - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on August 4, where it recorded a net buy of -7.94 million yuan [1].

Core Points - The stock price of NuoVivian has decreased by 2.07% to 21.76 CNY per share, with a total market capitalization of 8.655 billion CNY [1] - The company has experienced a year-to-date stock price decline of 1.18%, with a 4.27% drop over the last five trading days [1] - NuoVivian's main business includes the research and development of functional proteins and high molecular organic materials, with a revenue composition of 81.86% from biological reagents [1] Financial Performance - As of September 30, NuoVivian reported a total of 9,447 shareholders, an increase of 9.90% from the previous period [2] - For the period from January to September 2025, the company achieved a revenue of 952 million CNY, a year-on-year decrease of 3.40% [2] - The net profit attributable to the parent company was 6.6152 million CNY, reflecting a significant year-on-year decrease of 63.57% [2] Dividend Information - Since its A-share listing, NuoVivian has distributed a total of 731 million CNY in dividends, with 611 million CNY distributed over the past three years [3]

三房巷所属申万行业为：基础化工-化学纤维-涤纶。所属概念板块包括：低价、小盘、节能环保、新材 料、长三角一体化等。 截至9月30日，三房巷股东户数3.52万，较上期减少4.11%；人均流通股110719股，较上期增加4.28%。 2025年1月-9月，三房巷实现营业收入160.07亿元，同比减少12.49%；归母净利润-4.67亿元，同比减少 52.14%。 分红方面，三房巷A股上市后累计派现18.60亿元。近三年，累计派现5.84亿元。 12月3日，三房巷盘中下跌2.10%，截至10:09，报2.33元/股，成交1684.02万元，换手率0.18%，总市值 90.79亿元。 资金流向方面，主力资金净流出285.46万元，大单买入178.29万元，占比10.59%，卖出463.74万元，占 比27.54%。 三房巷今年以来股价涨26.63%，近5个交易日跌1.27%，近20日跌0.85%，近60日涨16.50%。 今年以来三房巷已经7次登上龙虎榜，最近一次登上龙虎榜为11月6日，当日龙虎榜净买入3526.04万 元；买入总计6131.75万元 ，占总成交额比38.50%；卖出总计2605.71万元 ，占总成交 ...

Core Viewpoint - Ximai Food's stock price has shown a significant increase of 51.37% year-to-date, indicating strong market performance despite a recent slight decline of 2.07% in intraday trading [2]. Company Overview - Ximai Food, established on August 1, 2001, and listed on June 19, 2019, is located in the High-tech Development Zone of Guilin, Guangxi Zhuang Autonomous Region. The company specializes in the research, production, and sales of oat-based food products [2]. - The revenue composition of Ximai Food includes: composite oat flakes (48.38%), pure oat flakes (36.62%), cold oat products (7.52%), and others (4.04%) [2]. Financial Performance - For the period from January to September 2025, Ximai Food achieved a revenue of 1.696 billion yuan, representing a year-on-year growth of 18.34%. The net profit attributable to the parent company was 132 million yuan, with a year-on-year increase of 21.90% [2]. - Since its A-share listing, Ximai Food has distributed a total of 470 million yuan in dividends, with 222 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Ximai Food reached 11,800, an increase of 7.63% from the previous period. The average circulating shares per person decreased by 7.09% to 18,980 shares [2]. - Notable institutional holdings include Baodao Huitai Preferred Mixed A (016840) as the fifth largest shareholder with 4.204 million shares, an increase of 602,600 shares from the previous period [3].